Dr. Hurvitz on Steps to Take With HER2-Positive Breast Cancer Research

Sara Hurvitz, MD
Published: Tuesday, Aug 16, 2016


Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses necessary steps that need to be taken in the field of HER2-positive breast cancer from a research perspective.

Researchers are beginning to have a deeper understanding of the different long-term and surgical outcomes of patients with hormone-receptor–positive, HER2-positive breast cancer compared with those who are HR-negative, Hurvitz explains. Outcomes related to PI3K activation status, she adds, may help inform decision-making and treatment options.

Looking at CDK4/6 inhibiton will also be an important area to study further, she adds. Future studies should explore combining CDK4/6 inhibitors with HER2-targeted agents as well as with endocrine therapy.
SELECTED
LANGUAGE

Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses necessary steps that need to be taken in the field of HER2-positive breast cancer from a research perspective.

Researchers are beginning to have a deeper understanding of the different long-term and surgical outcomes of patients with hormone-receptor–positive, HER2-positive breast cancer compared with those who are HR-negative, Hurvitz explains. Outcomes related to PI3K activation status, she adds, may help inform decision-making and treatment options.

Looking at CDK4/6 inhibiton will also be an important area to study further, she adds. Future studies should explore combining CDK4/6 inhibitors with HER2-targeted agents as well as with endocrine therapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x